Latest news with #CharlesRhyee
Yahoo
10-08-2025
- Business
- Yahoo
Cigna (CI) Pullback a Buying Opportunity, Says TD Cowen with a Buy Rating
The Cigna Group (NYSE:CI) is one of the best defensive stocks to invest in according to analysts. Cigna shares cracked over 10% on July 31 after the company reported its Q2 2025 quarterly results. Following the results, TD Cowen analyst Charles Rhyee reiterated a Buy rating on Cigna, maintaining a $387 price target. He believes the recent pullback in the shares was overdone and sees current levels as an attractive entry point. A health care professional consulting with patients in a state-of-the-art facility. While concerns around performance in the Health Insurance Exchange (HIX) segment weighed on sentiment, Rhyee expects the impact to be limited. He points to strength in other parts of the business, particularly Specialty and Care Services, as well as solid momentum in the company's Pharmacy Benefit Management (PBM) operations, which should help offset pressures. Rhyee also noted that management's Q3 guidance appears cautious, especially considering stepped-up investment in improving patient experience. Still, he remains confident in the company's earnings outlook, with robust EPS growth projections for 2025 and 2026 supporting his valuation. The Cigna Group (NYSE:CI) is a health services company that provides medical, pharmacy, behavioural health, dental, and supplemental insurance products. While we acknowledge the potential of CI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Most Oversold S&P 500 Stocks So Far in 2025 and 10 Most Oversold Semiconductor Stocks So Far in 2025. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10-08-2025
- Business
- Yahoo
Cigna (CI) Pullback a Buying Opportunity, Says TD Cowen with a Buy Rating
The Cigna Group (NYSE:CI) is one of the best defensive stocks to invest in according to analysts. Cigna shares cracked over 10% on July 31 after the company reported its Q2 2025 quarterly results. Following the results, TD Cowen analyst Charles Rhyee reiterated a Buy rating on Cigna, maintaining a $387 price target. He believes the recent pullback in the shares was overdone and sees current levels as an attractive entry point. A health care professional consulting with patients in a state-of-the-art facility. While concerns around performance in the Health Insurance Exchange (HIX) segment weighed on sentiment, Rhyee expects the impact to be limited. He points to strength in other parts of the business, particularly Specialty and Care Services, as well as solid momentum in the company's Pharmacy Benefit Management (PBM) operations, which should help offset pressures. Rhyee also noted that management's Q3 guidance appears cautious, especially considering stepped-up investment in improving patient experience. Still, he remains confident in the company's earnings outlook, with robust EPS growth projections for 2025 and 2026 supporting his valuation. The Cigna Group (NYSE:CI) is a health services company that provides medical, pharmacy, behavioural health, dental, and supplemental insurance products. While we acknowledge the potential of CI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Most Oversold S&P 500 Stocks So Far in 2025 and 10 Most Oversold Semiconductor Stocks So Far in 2025. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
25-06-2025
- Business
- Business Insider
Veradigm (MDRX) Receives a Buy from TD Cowen
In a report released yesterday, Charles Rhyee from TD Cowen maintained a Buy rating on Veradigm (MDRX – Research Report), with a price target of $8.00. The company's shares closed yesterday at $4.50. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Rhyee covers the Healthcare sector, focusing on stocks such as Charles River Labs, CVS Health, and Icon. According to TipRanks, Rhyee has an average return of 1.2% and a 47.49% success rate on recommended stocks. The word on The Street in general, suggests a Hold analyst consensus rating for Veradigm with a $5.00 average price target. The company has a one-year high of $11.80 and a one-year low of $3.00. Currently, Veradigm has an average volume of 210.6K.
